secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001104659-26-006619
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma receives Nasdaq bid price deficiency notice; 180 days to regain compliance
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice on Jan 15, 2026 for failing to maintain $1 minimum bid price for 30 consecutive business days.
- Has 180 calendar days, until July 14, 2026, to regain compliance by achieving $1 closing bid for 10 consecutive days.
- If non-compliant after period, may seek additional time; reverse split must be completed 10 business days before deadline.
- Common stock continues trading under symbol LIMN during compliance period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926006619/0001104659-26-006619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926006619/tm264095d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer